Duyuru • Mar 10
Cofinimmo SA(ENXTBR:COFB) dropped from Brussels BEL 20 Index Cofinimmo SA removed Duyuru • May 15
Cofinimmo SA announces Annual dividend, payable on May 22, 2025 Cofinimmo SA announced Annual dividend of EUR 4.3400 per share payable on May 22, 2025, ex-date on May 20, 2025 and record date on May 21, 2025. Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: €0.48 (vs €0.53 in 1Q 2023) First quarter 2024 results: EPS: €0.48 (down from €0.53 in 1Q 2023). Revenue: €87.0m (up 2.4% from 1Q 2023). Net income: €17.5m (flat on 1Q 2023). Profit margin: 20% (in line with 1Q 2023). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in the United Kingdom are expected to grow by 2.0%. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 08
Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022) Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €389.0m (up 5.8% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in the United Kingdom are expected to grow by 2.0%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. Reported Earnings • Feb 25
Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022) Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €349.0m (down 5.1% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 2.8% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to €71.80, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Health Care REITs industry globally. Total loss to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €88.36 per share. Duyuru • Oct 07
Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million. Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 2,785,805
Price\Range: €60
Transaction Features: Rule 144A Duyuru • Sep 27
An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million. An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million on September 25, 2023. Duyuru • Jul 14
Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home for € 7.35 million. Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home on for €7.35 million July 13, 2023.Cofinimmo SA (ENXTBR:COFB) completed the acquisition of The Park Nursing Home on July 13, 2023. Buying Opportunity • Jun 15
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 12%. The fair value is estimated to be €94.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 0.1% per annum. Earnings is also forecast to grow by 4.5% per annum over the same time period. Buying Opportunity • May 19
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 11%. The fair value is estimated to be €95.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 1.7% per annum. Earnings is also forecast to grow by 6.6% per annum over the same time period. Upcoming Dividend • May 08
Upcoming dividend of €4.34 per share at 7.2% yield Eligible shareholders must have bought the stock before 15 May 2023. Payment date: 17 May 2023. Trailing yield: 7.2%. Within top quartile of British dividend payers (5.7%). Higher than average of industry peers (6.5%). Reported Earnings • May 03
First quarter 2023 earnings released: EPS: €0.53 (vs €5.28 in 1Q 2022) First quarter 2023 results: EPS: €0.53 (down from €5.28 in 1Q 2022). Revenue: €85.0m (up 6.3% from 1Q 2022). Net income: €17.5m (down 90% from 1Q 2022). Profit margin: 21% (down from 209% in 1Q 2022). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 22
Full year 2022 earnings released: EPS: €15.09 (vs €8.78 in FY 2021) Full year 2022 results: EPS: €15.09 (up from €8.78 in FY 2021). Revenue: €325.1m (down 5.2% from FY 2021). Net income: €482.9m (up 86% from FY 2021). Net asset value (NAV) per share: €118 (flat on FY 2021). The current share price is 28% lower than NAV per share. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 30
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: €76.6m (up 6.2% from 3Q 2021). Net income: €148.3m (up 103% from 3Q 2021). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the REITs industry in the United Kingdom. Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment deteriorated over the past week After last week's 17% share price decline to €83.90, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 8x in the REITs industry in the United Kingdom. Total loss to shareholders of 28% over the past three years. Reported Earnings • Jul 30
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: €79.4m (up 7.6% from 2Q 2021). Net income: €157.6m (up 213% from 2Q 2021). Over the next year, revenue is expected to shrink by 3.0% compared to a 7.1% growth forecast for the industry in the United Kingdom. Board Change • Jun 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Michael Zahn was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • May 09
Upcoming dividend of €4.20 per share Eligible shareholders must have bought the stock before 16 May 2022. Payment date: 18 May 2022. Trailing yield: 4.9%. Within top quartile of British dividend payers (4.8%). Higher than average of industry peers (3.2%). Reported Earnings • May 01
First quarter 2022 earnings released First quarter 2022 results: Revenue: €79.2m (up 12% from 1Q 2021). Net income: €167.0m (up 271% from 1Q 2021). Over the next year, revenue is forecast to decline by 4.3% while the industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 5% per year. Board Change • Apr 28
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 25
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: €8.22 (up from €4.50 in FY 2020). Revenue: €299.6m (up 2.3% from FY 2020). Net income: €260.3m (up 118% from FY 2020). Profit margin: 87% (up from 41% in FY 2020). Revenue missed analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 12% while thereits industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 1% per year. Board Change • Feb 25
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Feb 25
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 29
Third quarter 2021 earnings released: EPS €2.44 (vs €1.45 in 3Q 2020) Third quarter 2021 results: Revenue: €72.6m (up 123% from 3Q 2020). Net income: €73.1m (up 87% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Board Change • Oct 22
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 03
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • May 10
Upcoming dividend of €4.06 per share Eligible shareholders must have bought the stock before 17 May 2021. Payment date: 19 May 2021. Trailing yield: 4.6%. Within top quartile of British dividend payers (4.0%). Higher than average of industry peers (3.0%). Reported Earnings • May 01
First quarter 2021 earnings released: EPS €1.67 (vs €1.64 in 1Q 2020) The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €71.0m (down 20% from 1Q 2020). Net income: €45.1m (up 6.9% from 1Q 2020). Profit margin: 64% (up from 48% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Reported Earnings • Apr 15
Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €292.7m (up 2.6% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 41% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Reported Earnings • Feb 28
Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €259.2m (down 9.2% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 46% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Feb 28
Revenue beats expectations Revenue exceeded analyst estimates by 3.3%. Over the next year, revenue is expected to shrink by 1.1% compared to a 4.8% decline forecast for the REITs industry in the United Kingdom. Is New 90 Day High Low • Feb 09
New 90-day high: €129 The company is up 1.0% from its price of €129 on 10 November 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the REITs industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €152 per share. Reported Earnings • Jan 17
Third quarter 2020 earnings released: EPS €1.45 Third quarter 2020 results: Revenue: €32.5m (up 9.0% from 3Q 2019). Net income: €39.2m (down 37% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.